FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …

Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …

DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to
myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that …

Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival
after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive …

Acute myeloid leukemia (AML) can be treated with either high-or low-intensity regimens.
Highly sensitive assays for measurable residual disease (MRD) now allow for a more …

PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit
patients with acute myeloid leukemia (AML) improves remission rates and survival …

Despite recent advances in acute myeloid leukemia (AML) molecular characterization and
targeted therapies, a majority of AML cases still lack therapeutically actionable targets. In …

Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in
older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated …

Background Many older patients with acute myeloid leukaemia die or cannot undergo
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …

Progress with intensive chemotherapy and supportive care measures has improved survival
in newly diagnosed acute myeloid leukemia (AML). Predicting outcome helps in treatment …